Business
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22 in San Diego, California. The presentations will highlight preclinical data from three potential first-in-class programs from IDEAYA's clinical stage pipeline: IDE034, a PTK7/B7H3 bi-specific topoisomerase-1 (TOP1) antibody-drug conjugate (ADC); IDE574, a potent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7; and IDE892, an MTA-cooperative inhibitor of PRMT5. The company is currently conducting Phase 1 clinical studies to evaluate safety, tolerability, PK and efficacy of these three programs across a broad range of large solid tumor indications, including lung, colorectal, pancreatic, breast, and prostate cancer.\n \n \n \n \n \n \n \n\"We are excited for the opportunity to showcase data from our earlier stage clinical pipeline at this year's AACR. These programs align closely with our clinical focus within TOP1 ADCs and DNA damage repair (DDR) mechanisms, synthetic lethality and modulation of epigenetic pathways to overcome resistance mechanisms in cancer. Our goal is to identify first-in-class and best-in-class product profiles to deliver robust monotherapy efficacy and rational combinations that have the potential to drive deeper, more durable responses for patients living with cancer,\" said Michael White, Ph.D., Chief Scientific Officer of IDEAYA Biosciences.Details of the poster presentations are as follows:Author: Munoz Delgado, D. et al.Title: IDE034, A bispecific antibody-drug conjugate co-targeting PTK7 and B7-H3, exhibits avidity-driven selectivity and enhanced antitumor activity versus mono-specific ADCsPoster Number: 232Session Title: DNA Damage and Repair 1Date and Time: Sunday, April 19, 2026 at 2:00pm-5:00pm PDTAuthor: Gupta, M. et al.Title: The KAT6/7 inhibitor IDE574 disrupts tumor lineage identity and drug tolerance to deliver robust antitumor activity in biomarker selected indicationsPoster Number: 4483Session Title: Epigenetic Modulators 1Date and Time: Tuesday, April 21, 2026 at 9:00am-12:00pm PDTAuthor: Rao, A. et al.Title: IDE892 is a highly potent and selective PRMT5 inhibitor...